Pacira BioSciences, Inc. (PCRX) stock
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)
Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –
Pacira BioSciences profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Pacira BioSciences's profit margin for the twelve months ending Jun 30, 2026 was 2.0%. For fiscal 2025 it was 1.0%, against -14.2% the year before. The highest annual figure on record is 33.9% in fiscal 2020.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.0% | +15.2 |
| FY2024 | Dec 31, 2024 | -14.2% | −20.4 |
| FY2023 | Dec 31, 2023 | 6.2% | +3.8 |
| FY2022 | Dec 31, 2022 | 2.4% | −5.4 |
| FY2021 | Dec 31, 2021 | 7.8% | −26.1 |
| FY2020 | Dec 31, 2020 | 33.9% | +36.5 |
| FY2019 | Dec 31, 2019 | -2.6% | −2.5 |
| FY2018 | Dec 31, 2018 | -0.1% | +14.7 |
| FY2017 | Dec 31, 2017 | -14.9% | −1.1 |
| FY2016 | Dec 31, 2016 | -13.7% | −14.5 |
| FY2015 | Dec 31, 2015 | 0.7% | +7.7 |
| FY2014 | Dec 31, 2014 | -6.9% | +67.8 |
| FY2013 | Dec 31, 2013 | -74.7% | +59.1 |
| FY2012 | Dec 31, 2012 | -133.8% | +142.4 |
| FY2011 | Dec 31, 2011 | -276.2% | −89.7 |
| FY2010 | Dec 31, 2010 | -186.4% | +24.9 |
| FY2009 | Dec 31, 2009 | -211.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 2.4% | +5.1 |
| Q1 FY2026 | Mar 31, 2026 | 1.6% | −1.2 |
| Q4 FY2025 | Dec 31, 2025 | 0.8% | −7.7 |
| Q3 FY2025 | Sep 30, 2025 | 3.0% | +88.1 |
| Q2 FY2025 | Jun 30, 2025 | -2.7% | −13.3 |
| Q1 FY2025 | Mar 31, 2025 | 2.8% | −2.5 |
| Q4 FY2024 | Dec 31, 2024 | 8.6% | −5.2 |
| Q3 FY2024 | Sep 30, 2024 | -85.1% | −91.7 |
| Q2 FY2024 | Jun 30, 2024 | 10.6% | −4.6 |
| Q1 FY2024 | Mar 31, 2024 | 5.4% | +17.6 |
| Q4 FY2023 | Dec 31, 2023 | 13.7% | +19.6 |
| Q3 FY2023 | Sep 30, 2023 | 6.6% | +7.0 |
| Q2 FY2023 | Jun 30, 2023 | 15.2% | +3.5 |
| Q1 FY2023 | Mar 31, 2023 | -12.2% | −16.5 |
| Q4 FY2022 | Dec 31, 2022 | -5.9% | −2.7 |
| Q3 FY2022 | Sep 30, 2022 | -0.4% | −14.2 |
| Q2 FY2022 | Jun 30, 2022 | 11.7% | −2.3 |
| Q1 FY2022 | Mar 31, 2022 | 4.3% | −4.4 |
| Q4 FY2021 | Dec 31, 2021 | -3.2% | −14.3 |
| Q3 FY2021 | Sep 30, 2021 | 13.8% | −96.9 |
| Q2 FY2021 | Jun 30, 2021 | 14.1% | +23.7 |
| Q1 FY2021 | Mar 31, 2021 | 8.7% | +1.0 |
| Q4 FY2020 | Dec 31, 2020 | 11.1% | +15.1 |
| Q3 FY2020 | Sep 30, 2020 | 110.8% | +116.6 |
| Q2 FY2020 | Jun 30, 2020 | -9.6% | −12.3 |
| Q1 FY2020 | Mar 31, 2020 | 7.7% | +10.8 |
| Q4 FY2019 | Dec 31, 2019 | -4.0% | −12.7 |
| Q3 FY2019 | Sep 30, 2019 | -5.8% | −5.0 |
| Q2 FY2019 | Jun 30, 2019 | 2.7% | −0.4 |
| Q1 FY2019 | Mar 31, 2019 | -3.0% | +11.3 |
| Q4 FY2018 | Dec 31, 2018 | 8.7% | +2.9 |
| Q3 FY2018 | Sep 30, 2018 | -0.8% | +10.5 |
| Q2 FY2018 | Jun 30, 2018 | 3.0% | +30.9 |
| Q1 FY2018 | Mar 31, 2018 | -14.3% | +14.4 |
| Q4 FY2017 | Dec 31, 2017 | 5.8% | +11.3 |
| Q3 FY2017 | Sep 30, 2017 | -11.3% | +21.1 |
| Q2 FY2017 | Jun 30, 2017 | -27.8% | – |
| Q1 FY2017 | Mar 31, 2017 | -28.7% | – |
| Q4 FY2016 | Dec 31, 2016 | -5.4% | – |
| Q3 FY2016 | Sep 30, 2016 | -32.4% | – |
See a number that looks wrong?